Clinical Cancer Drugs - Volume 4, Issue 1, 2017

Background: In recent times, miRNA has been able to catch the significant attention of scientists worldwide. This small part of non-coding RNA has finally been recognized for its enormous potential for cleavage, m-RNA degradation, and translational modifications. Moreover, miRNA has now been included in the list of quite important class of blood based biomarkers, which shows their specific signatures as circulating microRN Read More

Objective: Emergence of nitrogen mustards and their derivatives as DNA alkylating agent and their expanding anti-cancer applicability did fuel up massive efforts directed towards the design of anticancer agents in clinical practice. Considerable progress in this field has been achieved in the last few decades. Rich panoply of literature has illustrated the rather underexploited or completely novel therapeutic approaches based Read More

Background: With 23% of all new tumour cases, breast cancer is the most common cancer among women worldwide, and is the second leading cause of cancer deaths in women after lung cancer. Of more than one million cases of breast cancer diagnosed globally each year, a high percentage is characterized as triple-negative, lacking the oestrogen, progesterone and Her2/neu receptors. Lack of effective therapies, Read More

Background: Cisplatin is a commonly used anti-cancer drug. However, its use is associated with severe side effects including ototoxicity that affects a large fraction of cisplatin-treated patients. Approved therapies that reduce cisplatin-induced ototoxicity are lacking. Among the candidate therapeutics, dexamethasone stands out. There is extensive experience of its use in combination with cisplatin for the prevention of che Read More

Background: Brain tumors often go unnoticed in psychiatry population. Often the tumors remain silent before they present as behavioral changes or neurological signs. Brain tumors often present with psychiatric symptoms such as mood changes (depression or mania), psychotic symptoms, panic attacks, and changes in personality, or memory difficulties. The mengiomas of brain are often silent because of their slow growth. Read More

Background: To evaluate the prevalence of peripheral neuropathy associated with bortezomib and its relation to multiple myeloma versus other malignancies. Methods: This is a retrospective chart review study. Subjects who received bortezomib at HealthEast Care System for various malignancies were evaluated. Statistical analyses were performed using SAS Enterprise Guide software version 5.1. All comparison data Read More